2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
However, these groundbreaking companies are still looking at meaningful opportunities and catalysts that could help turn things around in the long run -- and perhaps even deliver life-changing returns. Here's why Iovance Biotherapeutics and CRISPR Therapeutics are worth serious consideration by risk-averse investors.
Iovance Biotherapeutics is a cancer specialist. Last year, it earned approval for Amtagvi, a medicine for advanced melanoma that's indicated for patients who have unsuccessfully undergone anti-PD-1 therapy. Amtagvi, a treatment made from cancer-fighting cells called tumor-infiltrating lymphocytes (TILs) in each patient's body, became the first of its kind to earn approval for treating a solid tumor.
Source Fool.com
